A Phase 2/3 interventional study of EXV-802 and Placebo in Agitation Associated With Alzheimer's Disease Dementia, sponsored by Exciva GmbH. Recruiting at 49 sites in 9 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Exciva GmbH · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in Alzheimer Disease with a site in Poland — 15 open to participants now, 25 under way, 14 of them phase 3. Alzheimer Disease · Poland.
Among the 113 studies in Alzheimer Disease with a site in Poland, this one is the 78th largest by planned enrollment of the 111 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 2/3, reaches primary completion later than 19 of the 24 other live ones, and was the 111th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →15 of the 113 studies in Alzheimer Disease with a site in Poland are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Poland, United States, Australia and 2 more countries
Ages 50–90
Daniel Maliszewski · Sites in Poland
Ages 18+
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Poland, Australia, Austria and 14 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Poland, United States, Argentina and 23 more countries
Ages 55–90
MapLight Therapeutics · Sites in Poland, United States, Argentina and 12 more countries
Ages 55–90
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 40 · Phase 3 65
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 500 across the 111 interventional studies, 25,542 across the 2 observational. Of the 85 that completed or were terminated, 52 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 113 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Exciva GmbH as lead sponsor.
Exciva GmbH has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
5 of the studies in Alzheimer Disease with a site in Poland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07107074ADvantage TherapeuticsEffects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE | 2026-12 |
| NCT04639050Hoffmann-La RocheBrainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 113 studies in Alzheimer Disease with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
This is a Phase 2/3 multicenter, double-blind, placebo-controlled, three-arm, multicenter study evaluating the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia. The diagnosis of agitation will be based on the consensus definition for agitation in patients with cognitive disorders developed by te International Psychogeriatric Association (IPA) Agitation Definition Work Group as well as neuroimaging performed after onset of dementia symptoms and a Core 1 AD biomarker.
The study will be conducted at up to 60 centers in the US, Canada and Europe.. Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study. Approximately 100 patients per arm will be randomized (300 total).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be assigned to treatment with EXV-802 capsules administered twice a day over a 6-week period.
Drug: EXV-802
Participants will be assigned to treatment with placebo capsules administered twice a day over a 6-week period.
Drug: Placebo
Participants will be assigned to treatment with EXV-801 capsules administered twice a day over a 6-week period.
Drug: EXV-801
Specified dose twice daily
Also known as: Dextromethorphan + EXV-801
Specified dose twice daily
Specified dose twice daily
Also known as: deramciclane
Changes from baseline to endpoint (Week 6) in the Cohen-Mansfield Agitation Inventory - International Psychogeriatric Association (CMAI-IPA) score
The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviors while lower scores indicate lower frequency of agitated behaviors The CMAI-IPA includes 19 items that were mapped to IPA agitation domains. The total score ranges from 19 to 133 with higher scores indicating more severity.
Time frame: Baseline to Week 6
Changes from baseline to endpoint (Week 6) in the Clinical Global Impression of Severity of Illness (CGI-S) score as related to symptoms of agitation
The CGI-S is an observer-rated scale that measures illness severity. The CGI-S is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = extremely ill) that assessed the severity of agitation in this study. Higher scores indicate severe agitation, while the lower scores indicate little or no agitation.
Time frame: Baseline to Week 6
Changes from baseline to endpoint (Week 6) in the Neuropsychiatric Inventory - Clinician (NPI-C) Caregiver Distress score for Agitation and Aggression domains
The NPI-C is a retrospective interview covering 14 neuropsychiatric symptom domains. The NPI-C version of the NPI scale was designed to be administered by the clinician to the participant and the caregiver. The caregiver is first asked to provide frequency, severity, and distress ratings for each individual item across the domains. Frequency is rated on a scale from 0 to 4. Severity is rated on a scale from 0 to 3. Separately, the rater interviews the patient to assess frequency (0 to 4) of each item. Clinician rating of clinical impression is a severity rating (0 to 3) based on all available clinical and interview information. For this endpoint, the caregiver distress will be analyzed for the agitation and aggression domains. Caregiver distress is rated on a scale from 0 to 5 with a total score range of 0 to 10 across the 2 domains. Higher scores indicate greater caregiver distress.
Time frame: Baseline to Week 6
Changes from baseline to endpoint (Week 6) in the Neuropsychiatric Inventory - Clinician (NPI-C) Irritability/Liability Domain score
The NPI-C is a retrospective interview covering 14 neuropsychiatric symptom domains. The NPI-C version of the NPI scale was designed to be administered by the clinician to the participant and the caregiver. The caregiver is first asked to provide frequency, severity, and distress ratings for each individual item across the domains. Frequency is rated on a scale from 0 to 4. Severity is rated on a scale from 0 to 3. Separately, the rater interviews the patient to assess frequency (0 to 4) of each item. Clinician rating of clinical impression is a severity rating (0 to 3) based on all available clinical and interview information. The score for the irritability/lability domain is the sum of clinical impression ratings of all items. There are 12 items in the irritability/lability domain. The minimum score for the irritability/lability domain is 0 and maximum score per domain is 36, with higher scores indicate greater symptom severity.
Time frame: Baseline to Week 6
Changes from baseline to endpoint (Week 6) in the Neuropsychiatric Inventory - Clinician (NPI-C) Sleep Disorders Domain score
The NPI-C is a retrospective interview covering 14 neuropsychiatric symptom domains. The NPI-C version of the NPI scale was designed to be administered by the clinician to the participant and the caregiver. The caregiver is first asked to provide frequency, severity, and distress ratings for each individual item across the domains. Frequency is rated on a scale from 0 to 4. Severity is rated on a scale from 0 to 3. Separately, the rater interviews the patient to assess frequency (0 to 4) of each item. Clinician rating of clinical impression is a severity rating (0 to 3) based on all available clinical and interview information. The score for the sleep disorders domain is the sum of clinical impression ratings of all items. There are 8 items in the sleep disorders domain. The minimum score for the sleep disorders domain is 0 and maximum score per domain is 24, with higher scores indicate greater symptom severity.
Time frame: Baseline to Week 6
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.
Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 70. This study's planned 35 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.